Sanofi
SNY · NasdaqPharmaceutical Preparations · Fiscal year ends Dec 31 · Reports in EUR
Net income was EUR 7.9B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cost of revenue | EUR 12.3B | EUR 11.9B | EUR 12.6B | EUR 13.2B | EUR 13B |
| Gross profit | EUR 26.9B | EUR 28.7B | EUR 29B | EUR 31.1B | EUR 33.7B |
| Research & development | EUR 5.7B | EUR 6.5B | EUR 6.5B | EUR 7.4B | EUR 7.8B |
| Selling, general & admin | EUR 9.6B | EUR 8.7B | EUR 8.9B | EUR 9.2B | EUR 9.5B |
| Operating income | EUR 8.1B | EUR 10.2B | EUR 7B | EUR 7.3B | EUR 6.3B |
| Interest expense | EUR 368M | EUR 430M | EUR 1.3B | EUR 1.1B | EUR 563M |
| Income tax | EUR 1.6B | EUR 1.9B | EUR 1B | EUR 1.2B | EUR 1B |
| Net income | EUR 6.3B | EUR 8.5B | EUR 5.4B | EUR 5.6B | EUR 7.9B |
Balance sheet
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | EUR 10.1B | EUR 12.7B | EUR 8.7B | EUR 7.4B | EUR 7.7B |
| Inventory | EUR 8.7B | EUR 9B | EUR 9.7B | EUR 9.4B | EUR 10.2B |
| Current assets | – | EUR 34.1B | EUR 30.7B | EUR 42.6B | EUR 31B |
| Net PP&E | EUR 10B | EUR 9.9B | EUR 10.2B | EUR 10.1B | EUR 10.1B |
| Goodwill | EUR 48.1B | EUR 49.9B | EUR 49.4B | EUR 43.4B | EUR 41.3B |
| Total assets | EUR 120B | EUR 127B | EUR 126B | EUR 133B | EUR 127B |
| Current liabilities | – | EUR 24B | EUR 24.2B | EUR 29.2B | EUR 28.3B |
| Shareholders' equity | EUR 68.7B | EUR 74.8B | EUR 74B | EUR 77.5B | EUR 71.4B |
Cash flow
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | EUR 10.5B | EUR 10.5B | EUR 10.3B | EUR 9.1B | EUR 10.8B |
Key ratios
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating income growth (YoY) | – | 25.1% | −31.5% | 4.2% | −12.5% |
| Return on equityBlank when equity is negative | 9.1% | 11.3% | 7.3% | 7.2% | 11.0% |
| ROCEEBIT ÷ (assets − current liabilities) | – | 9.9% | 6.8% | 7.0% | 6.4% |
| Cash conversion (CFO ÷ net income) | 1.68x | 1.24x | 1.89x | 1.62x | 1.37x |
| Inventory days | 260 | 275 | 279 | 261 | 286 |
| Interest cover | 22.1x | 23.6x | 5.38x | 6.76x | 11.3x |
| Current ratio | – | 1.42x | 1.27x | 1.46x | 1.09x |
Recent filings
More in Pharmaceutical Preparations
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.